ANAB vs KALV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Sell and KALV is a StrongSell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANAB’s FA Score shows that 0 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).
- ANAB’s FA Score: 0 green, 5 red.
- KALV’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANAB’s TA Score shows that 3 TA indicator(s) are bullish while KALV’s TA Score has 4 bullish TA indicator(s).
- ANAB’s TA Score: 3 bullish, 4 bearish.
- KALV’s TA Score: 4 bullish, 6 bearish.
Price Growth
ANAB (@Biotechnology) experienced а -4.51% price change this week, while KALV (@Biotechnology) price change was -5.83% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +1.90%, and the average quarterly price growth was -0.55%.
Reported Earning Dates
ANAB is expected to report earnings on Nov 07, 2024.
KALV is expected to report earnings on Dec 05, 2024.
Industries' Descriptions
@Biotechnology (+0.72% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ANAB | KALV | ANAB / KALV | |
| Capitalization | 1.13B | 475M | 239% |
| EBITDA | -141.06M | -131.18M | 108% |
| Gain YTD | 79.785 | -14.367 | -555% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 30.5M | 0 | - |
| Total Cash | 351M | 210M | 167% |
| Total Debt | 16.9M | 7.32M | 231% |
ANAB | KALV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 36 | 61 | |
P/E GROWTH RATING 1..100 | 81 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KALV's Valuation (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for ANAB (95) in the Biotechnology industry. This means that KALV’s stock grew somewhat faster than ANAB’s over the last 12 months.
KALV's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ANAB (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to ANAB’s over the last 12 months.
KALV's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as ANAB (99) in the Biotechnology industry. This means that KALV’s stock grew similarly to ANAB’s over the last 12 months.
ANAB's Price Growth Rating (36) in the Biotechnology industry is in the same range as KALV (61) in the Pharmaceuticals Other industry. This means that ANAB’s stock grew similarly to KALV’s over the last 12 months.
ANAB's P/E Growth Rating (81) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that ANAB’s stock grew similarly to KALV’s over the last 12 months.
| ANAB | KALV | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 86% |
| Advances ODDS (%) | 2 days ago 78% | 3 days ago 80% |
| Declines ODDS (%) | 5 days ago 78% | 5 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 80% |
| Aroon ODDS (%) | 3 days ago 90% | 2 days ago 83% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BGGSX | 23.79 | N/A | N/A |
| Baillie Gifford US Equity Growth I | |||
| SSFRX | 428.51 | -0.85 | -0.20% |
| State Street Equity 500 Index R | |||
| BSGRX | 13.44 | -0.09 | -0.67% |
| BlackRock Advantage Small Cap Gr R | |||
| IGNCX | 13.15 | -0.10 | -0.75% |
| Delaware Ivy Natural Resources C | |||
| TSONX | 14.31 | -0.16 | -1.11% |
| Nuveen International Res Eq R6 | |||
ANAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with ABSI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then ABSI could also see price increases.
| Ticker / NAME | Correlation To ANAB | 1D Price Change % | ||
|---|---|---|---|---|
| ANAB | 100% | +2.61% | ||
| ABSI - ANAB | 38% Loosely correlated | +0.12% | ||
| KALV - ANAB | 38% Loosely correlated | -4.64% | ||
| ALLO - ANAB | 38% Loosely correlated | -3.61% | ||
| AMRN - ANAB | 38% Loosely correlated | -2.05% | ||
| PLRX - ANAB | 38% Loosely correlated | -3.72% | ||
More | ||||
KALV and
Correlation & Price change
A.I.dvisor indicates that over the last year, KALV has been loosely correlated with IDYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then IDYA could also see price increases.
| Ticker / NAME | Correlation To KALV | 1D Price Change % | ||
|---|---|---|---|---|
| KALV | 100% | -4.64% | ||
| IDYA - KALV | 42% Loosely correlated | -0.77% | ||
| PLRX - KALV | 42% Loosely correlated | -3.72% | ||
| ATXS - KALV | 42% Loosely correlated | +2.51% | ||
| FATE - KALV | 41% Loosely correlated | -3.25% | ||
| RYTM - KALV | 40% Loosely correlated | -3.21% | ||
More | ||||